<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260467</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB34285</org_study_id>
    <secondary_id>054835-002</secondary_id>
    <nct_id>NCT01260467</nct_id>
  </id_info>
  <brief_title>Memantine for Recurrent Glioblastoma</brief_title>
  <official_title>A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a medication called memantine is effective in
      treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor,
      which is thought to be involved in the growth of brain tumors. It has previously been studied
      for other types of conditions, such as Alzheimer's disease, but it has not yet been evaluated
      in the treatment of brain tumors. The investigators will also be determining how common it is
      for patients with brain tumors to have side effects to memantine. Memantine will be taken by
      mouth twice a day.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Month Progression-free Survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>This study will look at the number of participants who develop adverse events or side effects thought to be related to the memantine.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>memantine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memantine</intervention_name>
    <description>10 milligrams orally twice a day</description>
    <arm_group_label>memantine arm</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven World Health Organization (WHO) grade IV gliomas.
             Patients will be eligible if the original histology was a grade II or grade III glioma
             as long as a subsequent histological diagnosis of a grade IV glioma is confirmed.

          -  Patients must have shown unequivocal radiographic evidence for tumor progression by
             magnetic resonance imaging (MRI) scan. A scan should be performed within 10 days prior
             to registration and on a steroid dose that has been stable for at least 5 days. If the
             steroid dose is increased between the date of imaging and registration a new baseline
             MRI is required.

          -  Patients with prior therapy that included interstitial brachytherapy or stereotactic
             radiosurgery (including gamma-knife or cyber-knife) must have confirmation of true
             progressive disease rather than radiation necrosis based upon either positron emission
             tomography (PET) or Thallium scanning, magnetic resonance spectroscopy (MRS), magnetic
             resonance perfusion, or surgical documentation of disease. The decision of which
             modality to use to make this confirmation will be at the discretion of the
             investigator.

          -  All patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study. Patients must have signed an authorization for
             the release of their protected health information.

          -  Age greater than 18 years old, and with a life expectancy greater than 8 weeks.

          -  Karnofsky Performance Status greater or equal to 60

          -  Patients must have an interval of at least 28 days from any investigational agent or
             from prior cytotoxic therapy, 6 weeks from prior nitrosureas, 3 weeks from
             procarbazine and 2 weeks from vincristine.

          -  Patients must have failed prior radiotherapy and must have an interval of greater than
             42 days from completion of initial radiation therapy to study entry or 28 days since
             radiation therapy used for recurrent tumor.

          -  Since memantine is not associated with myelosuppression, patients with persistent
             effects on bone marrow function from prior cytotoxic chemotherapies will be eligible
             as long as: white blood cells &gt; 1,000/Âµl, absolute neutrophil count &gt; 500/mm3,
             platelet count of &gt; 50,000/mm3, and hemoglobin &gt; 8 gm/dl). Patients must have adequate
             liver function and adequate renal function before starting therapy. These tests must
             be performed within 2 weeks prior to treatment initiation. Eligibility level for
             hemoglobin may be reached by transfusion.

          -  Patients must have a calculated creatinine clearance &gt; 30 milliliters/minute.

        Exclusion Criteria:

          -  Patients who are within 3 months of treatment with radiation and concurrent
             temozolomide will not be eligible unless there are new enhancing abnormalities outside
             the high dose radiation fields (i.e beyond the 80% isodose line) or surgical
             demonstration of active tumor.

          -  Patients must not be pregnant and must agree to practice adequate contraception. Women
             of childbearing potential must have a negative pregnancy test documented within 7 days
             prior to registration. Women must not be breastfeeding.

          -  Patients with a history of other cancer (except non-melanoma skin cancer or cancer of
             the cervix), unless in complete remission for at least 3 years are ineligible.

          -  Patients must not have any significant medical illnesses or other history that in the
             investigator's opinion cannot be adequately controlled with appropriate therapy or
             would compromise the patient's ability to tolerate this therapy.

          -  Patients must not have any disease that will obscure toxicity or dangerously alter
             drug metabolism.

          -  Patients must not have prior or concurrent use of memantine or treatment with other
             N-methyl D-asparate (NMDA) receptor blocking therapies.

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          -  Inability or unwillingness of subject or legal guardian/representative to give written
             informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nimish Mohile, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>November 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2015</results_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Nimish Mohile</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Agent Memantine Group</title>
          <description>memantine:10 milligrams orally twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Agent Memantine Group</title>
          <description>memantine:10 milligrams orally twice a day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>30 months</time_frame>
        <population>not evaluated due to poor patient accrual</population>
        <group_list>
          <group group_id="O1">
            <title>Single Agent Memantine Group</title>
            <description>memantine:10 milligrams orally twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>not evaluated due to poor patient accrual</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Month Progression-free Survival</title>
        <time_frame>24 months</time_frame>
        <population>not evaluated due to poor patient accrual</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine Arm</title>
            <description>memantine: 10 milligrams orally twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Progression-free Survival</title>
          <population>not evaluated due to poor patient accrual</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>This study will look at the number of participants who develop adverse events or side effects thought to be related to the memantine.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>No adverse events reported.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>This study will look at the number of participants who develop adverse events or side effects thought to be related to the memantine.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Agent Memantine Group</title>
          <description>NO data to report</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Serventi Research Associate</name_or_title>
      <organization>University of Rochester Medical Center</organization>
      <phone>585-276-3971</phone>
      <email>jennifer_serventi@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

